Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients

Blood

Volumn 98, Issue 2, 2001, Pages 492-494

  Barlogie, Bart ^a,b   Desikan, Raman ^a,b   Eddlemon, Paul ^a,b   Spencer, Trey ^a,b   Zeldis, Jerome ^a,b   Munshi, Nikhil ^a,b   Badros, Ashrof ^a,b   Zangari, Maurizio ^a,b   Anaissie, Elias ^a,b   Epstein, Joshua ^a,b   Shaughnessy, John ^a,b   Ayers, Dan ^a,b   Spoon, Dan ^a,b   Tricot, Guido ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; THALIDOMIDE;

ARTICLE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CELL LABELING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DEPRESSION; DOSE RESPONSE; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SEDATION; SENSORY NEUROPATHY; SOMNOLENCE; SURVIVAL RATE; TOXICITY; TREATMENT OUTCOME; TREMOR;

EID: 0035880229     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.2.492     Document Type: Article

References (21)

1. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
2. Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med. 1995;5:582-585.
3. Geitz H, Handt S, Zwingengerger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology. 1996;32:213-221.
4. Corral LG, Haslett PAJ, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs that are potent inhibitors of TNF-α. J Immunol. 1999;163:380-386.
5. D'Amato RJ, Loughman MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-4085.
6. + subset. J Exp Med. 1998;187:1885-1892.
7. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96;2943-4950.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
9. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
10. Cox DR. Regression models and life-tables (with discussion). J Royal Stat Soc Series B. 1972;34:187-220.
11. 2)-based high dose therapy [abstract]. Blood. 1998;92:1119a.
12. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Maim C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol. 2000;109:89-96.
13. Durie B, Stepan D. Efficacy of low dose thalidomide in multiple myeloma. Eur J Oncol. 2000;1:1-8.
14. Alexanian R, Weber D. Thalidomide for resistant and relapsing myeloma. Sem Hematol. 2000;37(suppl 3):22-25.
15. Yakoub-Agha I, Moreau P, Leyvraz S, et al. Thalidomide in patients with advanced myeloma: survival prognostic factors. Blood. 2000:96(suppl 1):167a.
16. Weber DM, Rankin K, Gavino M, et al. Thalidomide with dexamethasone for resistant multiple myeloma [abstract]. Blood. 2000;96(suppl 1):167a.
17. Rajkumar SV, Haymen S, Fonseca R, et al. Thalidomide plus dexamethasone and thalidomide alone as first-line therapy for newly diagnosed myeloma. Blood. 2000;96(suppl 1):168a.
18. Shaughnessy J, Zhan F, Tian E, et al. Global gene expression analysis shows loss of c-myc and IL-6 receptor gene mRNA after exposure of myeloma to thalidomide and IMiD [abstract]. Blood. 2000;96:579a.
19. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep vein thrombosis in multiple myeloma patients receiving thalidomide in combination with chemotherapy. Blood. In press.
20. Badros A, Zangari M, Bodenner D, et al. Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide [abstract]. Blood. 2000;96:285b.
21. Noopur R, Anderson K. Thalidomide: a revival story. N Engl J Med. 341:1606-0608, 1999.